St. Jude (STJ) Receives CE Mark for Genesis Neurostimulation System for PNS
Tweet
Share
E-mailGet Alerts STJ Hot Sheet
Join SI Premium – FREE
St. Jude Medical, Inc. (NYSE: STJ), reports it received European CE Mark approval for its Genesis neurostimulation system for peripheral nerve stimulation (PNS) of the occipital nerves for the management of the pain and disability associated with intractable chronic migraine.
The CE Mark approval was supported by the results of St. Jude Medical’s chronic migraine study, a randomized, double-blind, controlled study that collected data from 157 patients. On average, participants enrolled in the study suffered from headache 26 days per month.
The CE Mark approval was supported by the results of St. Jude Medical’s chronic migraine study, a randomized, double-blind, controlled study that collected data from 157 patients. On average, participants enrolled in the study suffered from headache 26 days per month.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- Nuvectis Pharma (NVCT) files $200M mixed shelf
- enVVeno Medical (NVNO) files $100M mixed shelf
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
